Abstract
Chondrosarcoma (CS) is the second most common primary malignant bone tumor, with a relatively high recurrence rate. However, an effective method that estimates whether pelvic CS will recur after surgery, which influences the formulation of a clinical treatment plan, remains lacking. To develop and validate a clinical radiomics nomograms based on 3D multiparametric magnetic resonance imaging (mpMRI) features and clinical characteristics that could estimate early recurrence (ER) (≤1 year) of pelvic CS. Retrospective. In all, 103 patients (ER = 41, non-ER = 62) with histologically proven CS were retrospectively analyzed and divided into a training set (n = 72) and a validation set (n = 31). 3.0T axial T1 -weighted (T1 -w), T2 -weighted (T2 -w), diffusion weighted imaging (DWI), contrast-enhanced T1 -weighted (CET1 -w). Risk factors (sex, age, type, grade, resection margins, etc.) associated with ER were evaluated. Five individual models based on T1 -w, T2 -w, DWI, CET1 -w, and clinical data were built. Then we compared the performance of models based on T1 -w, T2 -w, CET1 -w and their combination. Lastly, two nomograms based on the best model + clinical data and DWI + clinical data were built. The area under the receiver operating characteristic curve (AUC) and accuracy (ACC) were used to evaluate different models. Grade was the most important univariate clinical predictor of ER of pelvic CS patients (odds ratio [OR]1 = 4.616, OR2 = 8.939, P < 0.05). T1 -w + T2 -w + CET1 -w had a significantly higher performance than CET1 -w in the training set (P = 0.01). Radiomics features are more important than clinical characteristics in clinical radiomics nomograms, especially for multisequence combined features (OR = 3.208, P < 0.01). Clinical radiomics nomogram based on combined features (T1 -w + T2 -w + CET1 -w) + clinical data achieved an AUC of 0.891 and ACC of 0.857, followed by DWI + clinical data (AUC = 0.882, ACC = 0.760) in the validation set. The clinical radiomics nomogram had good performance in estimating ER of pelvic CS patients, which would be helpful in clinical decision-making. 4 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2020;51:435-445.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have